Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 111-117

  Klostergaard, J ^a   Auzenne, E ^a   Ghosh, S ^a   Farquhar, D ^a   Rivera, B ^a   Price, R E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CDDP; HA TXL; Intraperitoneal; MRI; Ovarian carcinoma xenograft; Serial imaging

Indexed keywords

CISPLATIN; COPOLYMER; HYALURONIC ACID; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARCINOMA CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG DOSE REGIMEN; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; LIFESPAN; MOUSE; MULTIPLE DRUG ABUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OVARY CARCINOMA; PERITONEUM TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FEASIBILITY STUDIES; FEMALE; HUMANS; HYALURONIC ACID; MAGNETIC RESONANCE IMAGING; MICE; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; POLYMERS; PREDICTIVE VALUE OF TESTS; SINGLE-BLIND METHOD; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645328822     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00502.x     Document Type: Article

References (23)

1. Rowinsky EK Donehower RC. Paclitaxel (Taxol) New Engl J Med 1995 332 1004 14.
2. Bankhead C. For ovarian cancer, an optimal treatment remains to be found. J Natl Cancer Inst 2004 96 96 7.
3. Tournigand C Louvet C Molitor JL et al. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol 2003 91 341 5.
4. Hovig E Rye PD Warren DJ Nustad K. CA-125: the end of the beginning. Tumour Biol 2001 22 345 7.
5. Cooper BC Sood AK Davis CS et al. Preoperative CA-125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002 100 59 64.
6. Petignat P Joris F Obrist R. How CA-125 is used in routine clinical practice. Eur J Cancer 2000 36 1933 7.
7. Tuxen MK Soletormos G Dombernowsky P. Serum tumor marker CA-125 for monitoring ovarian cancer during follow-up. Scand J Clin Lab Invest 2002 62 177 88.
8. Rustin GJ Marples M Nelstrop AE Mahmoudi M Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001 19 4054 7.
9. Tuxen MK Soletormos G Dombernowsky P. Serum tumour marker CA-125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001 84 1301 7.
10. Sugiyama T Nishida T Ushijima K et al. Detection of lymph node metastasis in ovarian carcinoma and uterine corpus carcinoma by preoperative computerized tomography or magnetic resonance imaging. J Obstet Gynaeacol 1995 21 551 6.
11. Coakley FV. Staging ovarian cancer: role of imaging. Radiol Clin North Am 2002 40 609 36.
12. Huber S Medl M Baumann L Czembirek H. Value of ultrasound and magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 2002 22 2501 7.
13. Lorenzen M Braun J Gehrckens A Nicolas V. Value of MRI, CT and findings in staging of gynecologic malignancies. Aktuelle Radiol 1998 8 266 72.
14. Ascher SM Takahama J Jha RC. Staging of gynecologic malignancies. Top Magn Reson Imaging 2001 12 105 29.
15. Kalpna M Zhang L Klostergaard J Donato NJ. Emergence of CDDP-resistant cells from OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity and increased apoptotic sensitivity to p53 gene replacement. Int J Gynecol Cancer 2000 10 105 14.
16. Hamilton TC Young RC McKoy WM et al. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983 43 5379 89.
17. Auzenne E Donato NJ Li C et al. Superior therapeutic profile of poly- l -glutamic acid-paclitaxel copolymer compared to Taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002 8 573 81.
18. Dini MM Jafari K Faiferman I. Cell-mediated cytotoxicity in preinvasive and invasive squamous cell carcinoma of the cervix. Obstet Gynecol 1980 55 728 31.
19. Buick RN Pullano R Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985 45 3668 76.
20. Luo Y Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999 10 755 63.
21. Luo Y Ziebell MR Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000 1 208 18.
22. Jennings D Hatton BN Guo J et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002 4 255 62.
23. Plaks V Koudinova N Nevo U et al. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia 2004 6 224 33.